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ICCA Tanzania 
Cancer patients’ pathways: evidence and implications for policy1 
               Working Paper 
Summary 
This Discussion Paper presents findings from a patient pathway survey conducted in 2019 with 62 
Tanzanian participants suffering from cancer or survivors of cancer. The paper looks at facilitators 
and barriers to accessing cancer care in Tanzania. A number of identified challenges that hinder 
patients from accessing care in a timely manner relate to costs, diagnosis and referrals. The paper 
highlights the social and economic burden faced by patients on the path to treatment. 
The research forms part of a larger collaborative project, Innovation for Cancer Care in Africa (ICCA). 
The survey included an innovative methodology, tracing in detail patients’ pathways through their 
experience of cancer from first symptoms to diagnosis to treatment and after.  Key findings in this 
paper include the following.  
 Late-stage presentation of cancer is acknowledged to be a serious impediment to effective 
treatment in Tanzania. The average delay for these patients between first going to a health 
facility with symptoms that were those of cancer, to diagnosis, was 2.13years. This delay is a 
central cause of late stage presentation for treatment.  
 In their search for a diagnosis, many patients have moved repeatedly between formal 
facilities as their (often severe) symptoms worsened. While most public sector patients had 
to move “up” the system, from district to zonal or national level hospitals to obtain a 
diagnosis, only 15% of all these movements between facilities were the result of a referral. 
Most were patients’ (and their families’) search for diagnosis.  
 Regional hospitals, to which many patients moved from district level, did not do well in 
terms of diagnosis; only 8 people were eventually diagnosed at regional level including none 
who began their pathways at that level.  
 Several patients had been well served by dispensaries and district hospitals: two directly 
diagnosed there, and several moving directly to the facility where diagnosed: there is thus 
some good practice at district level to be shared.  
 Two patients were diagnosed through screening, both after several moves between formal 
health facilities, evidencing both the importance of screening and the lack of effective 
investigation of symptoms within the system. 
 Out-of-pocket costs were high for patients in the period when they were seeking treatment, 
an average of over TZS 400,000. For those on lower household incomes in particular, this 
                                                          
1
 This ESRF Working Paper presents findings from a patients’ pathways survey conducted in 2019 with 62 
Tanzanian participants suffering from cancer or survivors of cancer. The research forms part of a larger project, 
Innovation for Cancer Care in Africa (ICCA). The support of the Economic and Social Research Council (ESRC) 
(UK) is gratefully acknowledged. The content of this working paper is the sole responsibility of the authors and 
does not necessarily reflect the views of the UK ESRC. In Tanzania, the project is led by Fortunata Songora 
Makene at ESRF, and the research brings together an interdisciplinary team encompassing sociologists, 
statisticians, economists, clinical oncologists and industrial pharmacists’ expertise. The larger project brings 
together researchers from Tanzania, Kenya, India and the UK to address the opportunities and challenges of 
linking industry and health systems in order to widen access to cancer care in Tanzania and Kenya. Research 
and Ethical Clearances were sought and obtained from NIMR, COSTECH, NBS, PORALG, and Regional Offices in 
Dar Es Salaam, Pwani (Coast) and Tabora, and the Open University, UK. 
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had imposed a major burden and source of impoverishment. This effect was worsened by 
the addition of transport costs of moving between facilities. 
 Patients starting in the private sector, generally with NHIF or private insurance, experienced 
shorter and more direct trajectories to diagnosis. Insurance was only partially financially 
protective before diagnosis, reducing on average but not eliminating out of pocket (OOP) 
spending.  
 Delays between diagnosis and treatment were much shorter: average 16 weeks to start of 
treatment. A cancer diagnosis triggered, on average, burdensome continuing costs: while 
half of respondents made no OOP payments after diagnosis, the average payments for all 
respondents were over TZS 1.6 million. Of those who made these payments, 80% had no 
insurance. 
 Over half of respondents said they had used a complementary or alternative form of care. 
For many this was prayer and faith healing, sometime associated with other forms of 
mosque or church support. Those who went to alternative healers and gave cost details had 
spent an average of nearly TZS half a million.  
 Free treatment at Ocean Road Cancer Institute (ORCI) is effective in protecting many lower 
income patients, who made up the majority of respondents interviewed at ORCI, from 
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1. Introduction 
Cancer is the second leading cause of death globally, and is responsible for about 9.6 million deaths 
in 2018 (WHO, 2018). Globally, about 1 in 6 deaths are due to cancer. Cancer is a sharply rising 
disease burden in Tanzania. According to WHO (2020) for Tanzania there was a total of 42,060 
cancer cases in 2018 and 28,610 cancer deaths in the same year. About 35,000 people develop 
cancer each year, and recent forecasts suggest that by 2020 this number will increase by 50% (URT, 
2017).Cancer is known to be diagnosed late, and services are concentrated in a few regional centres.  
High mortality rates result from late presentation by patients with potentially curable cancers. 
Access to treatment is hampered by a variety of factors including scarcity of essential items and cost 
of accessing care.  
Currently, there are a number of policies in place that provide access and reduce the burden on 
individuals with the chronic disease.  Institutional capacity and policy options can be limiting for 
cancer in Tanzania.  At the national level, the Tanzania Development Vision 2025 mentions the 
increasing incidence of NCDs like diabetes, hypertension, coronary heart diseases, and cancer and 
the need for a multi-sectoral approach to health interventions.   The Second Five Year Development 
Plan 2016-2020 (FYDP II) (2016) notes that diseases are major barriers to development, but there is 
no specific mention of NCDs including cancer.  The National Health Policy 2017 puts in place policies 
to address various forms of cancer and improvement of community access to cancer management 
and treatment.  In addition, Tanzania has a National Cancer Control Strategy (NCCS) 2013-2022 
(2013) which addresses cancer prevention, early detection, improvement of diagnosis and treatment 
including palliative care.  Furthermore, the NCCS aims at improving cancer surveillance, registration 
and research. 
This paper offers important insights into cancer care in Tanzania as it has been experienced in recent 
years by patients currently or recently undergoing treatment for a range of cancers.2 
2. Methods  
2.1 Ethical considerations 
A research permit and ethical approval was obtained from the National Institute for Medical 
Research (NIMR), Tanzania Commission for Science and Technology (COSTECH), the National Bureau 
of Statistics (NBS) and the President’s Office – Regional Administration and Local Government 
(PORALG) to adhere to Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research in accordance with Tanzania’s Research Policy and Standards. All informed consent 
included the ethical components stating the objectives and content of the study, privacy and data 
security, voluntary participation, the right to refuse to answer or skip any questions without 
consequences, and information on who to follow up regarding complaints or further information on 
the study. All participants signed the consent immediately prior to the interview. Enumerators were 
trained and received instruction on ethical data collection and informed consent prior to data 
collection.  For confidentiality, all raw data have been kept in a secure place accessible only to ESRF 
and Open University, UK researchers. Voice records of in-depth interviews will be destroyed after 
the study is finalized. 
                                                          
2
 The research team is grateful for the time and commitment of all their interviewees, many responding 
despite serious illness. The commitment of our interviewers Samwel Ebenezeri, Teddy Rucho, Nicholas 
Lusingu, Ikunda Njau, Rehema Paul, Wilfred Massau, Janeth Telekako, and Habambi Habambi in undertaking 
these interviews with sensitivity is appreciated. Thanks also to all participants who participated in feedback 
workshop held on the 10
th
 of December 2019. 
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2.2 Geographical locations and sampling  
Data for the study were collected from three regions in Tanzania Mainland that were purposively 
selected to support comparative analysis: Dar-es-Salaam, Pwani and Tabora Regions. Dar es Salaam 
is the commercial capital. It hosts the national cancer hospital at the Ocean Road Cancer Institute 
(ORCI) and the national level hospitals able to offer cancer care at Muhimbili and Mloganzila. Pwani 
and Tabora offer insights into patient experience close to and further from the resources of the 
commercial capital to the national hospitals.  
To recruit participants for the survey, patients who were undergoing cancer treatment at Ocean 
Road Cancer Institute were asked to participate, and 40 agreed to participate in the study. In 
addition, in Dar es Salaam, seven patients at Aga Khan Hospital were interviewed, and six cancer 
survivors. Outside Dar es Salaam, nine cancer patients at Kitete and Tumbi regional hospitals were 
also interviewed (Table 1). The medical staff in respective facilities assisted in identifying patients 
who could take part in our study. Cancer survivors were interviewed at the hospital where the 
contacts were obtained or alternative places convenient for them. The small numbers of participants 
in Kitete and Tumbi hospitals can be attributed to the fact that the regional hospitals are presently 
able to provide only initial screening/diagnosis for cancer patients. 
For interpretation of the findings presented in this paper, it is important to keep in mind that we 
interviewed only patients who were undergoing treatment, about to start treatment, or having 
completed treatment. There was no way to reach people who had dropped out of the system before 
or after diagnosis.  
Table 1 Survey participants by location of recruitment and interview 
Location Number of participants 
Ocean Road Cancer Institute, Dar es Salaam 40 
Kitete Hospital, Tabora 4 
Tumbi Hospital, Pwani 5 
Aga Khan Hospital, Dar es Salaam 7 
Cancer survivors, Dar es Salaam 6 
Total participants 62 
 
2.3 The survey instrument and data collection 
The survey for which we report the findings here was a demanding experience for interviewers and 
participants. The survey was developed in English then translated in Swahili for the Tanzanian 
Swahili speakers. The survey was administered through a tablet; subsequently the responses were 
translated into English. 
The interview began with structured questions eliciting some basic socio-demographic information 
from each participant (age, sex, schooling, marital status), plus information on income, place of 
residence and size of household, and occupational status, both current and before the illness. Other 
closed questions included the use of alternative health treatments; insurance arrangements; and 
participants’ social support and information networks. Open questions asked for reasons for use/ 
non-use of alternative healing, and views on the availability, affordability, adequacy, and 
acceptability of treatment and diagnostic practices. 
The core of the interview elicited a narrative account of each participants’ “pathway” since they first 
noted symptoms which were later identified as cancer. To elicit information about patients’ 
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journeys, the enumerator asked how long ago patients had experienced the first symptoms, and to 
use the following prompts for each step in the patient’s narrative: 
- What did you do? 
- Where was this? 
- What was done? 
- How much did it cost, and how much did you or your family/friends pay from your own 
funds? 
- Did any insurance cover part of the cost? Which, and how much? 
- How did you travel? 
- And then what happened? 
- When was this? 
Each pathwaywould contain as much or as little detail as the patient would want to or could share, 
so length and depth varied greatly among patients.  
Most interviews lasted for about one hour, although lasted for about to two hours. The average 
number of key events recorded was 10, but four patients reported as many as 30 key events. The 
process was stressful for interviewers as well as patients, since these are painful stories. The 
participants shared their stories either privately or in a room with several other patients who also 
provided peer support. Some interviews were interrupted because the patient needed medical 
attention or was too tired, and resumed only if that was the wish of the patient. Participants and 
their carers did express a wish to tell their stories and several said that they felt listened to.  
The survey data other than pathways were recorded on a tablet. The pathways section was recorded 
on paper to allow flexibility in compiling the narrative, and the information was transferred to the 
tablet at the end of each day. Workshops with the enumerators helped to capture the detail needed 
to analyse patients’ health seeking behaviour and experience.  
2.4 Methods of analysis 
Analysis of the participants’ narratives has used a mix of quantitative and qualitative methods. Each 
patient’s pathway was entered into the format of a matrix, where each row shows an event, starting 
from the first event, that is the first symptoms, and then following rows recording each event 
These pathways data have been analysed using Stata14. Data cleaning and interpretation for 
quantitative analysis have included measurement of time between major milestones for the patient: 
first symptoms, first entry into the formal health care system, cancer diagnosis, and start of cancer 
treatment. There are rich data on payments out of pocket for consultations, diagnostics and 
treatments, and the burden these payments impose on patients and their families. The quantitative 
analysis reported shows the experiences shared by survey participants may be related to their 
starting point within the health care system; their household’s ability to support their health care 
costs including support networks and whether they have insurance; and respondents’ use of 
alternative treatments.  
In addition, the replies to open ended questions, and aspects of the narratives, have been analysed 
using NVivo11 to code and link emerging themes. 
2.5 Innovative aspects of the pathways method  
The precise form in which the pathways approach is developed and used in this project is an original 
contribution to the literature. Its format and data recording approach is drawn from the economics 
literature on household time budget studies. There are some similarities and contrasts with the way 
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in which concepts of “pathways” are currently used in the health systems and clinical health 
management literature. That literature distinguishes clinical and care pathways from other patient 
pathways approaches.  
The literature on clinical pathways generally provides evaluations of treatment packages with a view 
to reduce costs and to improve outcomes by standardising treatment (Rotter et al. 2012; Dahlin and 
Raharjo 2019). Most of this literature is hospital based and is focused on defining best practice. A 
limitation of this approach, it has been noted, is that “the roles of patients and their relatives 
*are+…underreported” in the pathway definitions (de Bleser et al 2006). A somewhat broader 
approach is taken in the “care pathways” literature: here, pathways are normative ”tools to organise 
patient care” (Vanheacht et al 2012:28) or “assist in providing general guidelines” for care (Coughlan 
et al (2006:138). They are more likely to be nurse focussed and/or to include pathways outside a 
hospital setting. Vanheacht et al (2012) list related definitions of these pathways, and argue that it is 
hard to evaluate these pathways in practice, because they inevitably reflect complex interventions 
strongly dependent on context.  
Alongside this evaluation literature on clinical/care pathways, there is a related, more exploratory 
literature modelling patient flows, and examining the extent to which standard clinical pathways are 
adhered to. This involves tracing actual patients’ routes through care, using methodologies more 
akin to our own. These methods have been used to construct standardised pathways for clinicians 
and managers to implement e.g. in Russia (Kontsevaya et al 2018), and in Europe) Adeyemi et al 
2013). 
Finally, there is a smaller but growing literature on “patient pathways” used to understand patients’ 
experience and points of view (e.g. in Europe, Salamonsen et al 2016, and in Africa Kauye et al 2015; 
Mhalu et al 2019). Much of this latter research is qualitative, often with small numbers of 
respondents, and links to an expanding literature on “patient-centred care” (e.g. Kitson et al 2012). 
Some of the work focuses on patient’s pathways until they start treatment (e.g. for Africa, Kauye et 
al 2015; Mhalu et al 2019). Other studies follow the pathways through treatment (e.g. Salamondsen 
et al 2016). A systematic review of delayed presentation and diagnosis of breast cancer in African 
women (Espina et al 2017) distinguishes patient-mediated (e.g. socioeconomic status) and health 
system-mediated (e.g. referral problems) delays but makes the point that they are interrelated. That 
review addresses what they call “navigation pathways” followed by patients for accessing treatment, 
and the review also notes that none of the articles surveyed combined health care providers’ views 
with patients’ views, relying only on patients’ reporting.  
In this project, several aspects of the use of pathways are innovative. The sample size is larger than 
many previous qualitative patient pathways studies. The extent of the information recorded is 
unusually broad and detailed. And the use of quantitative methods to analyse the pathways, 
associated with qualitative analysis of themes, is original within the literature. From a qualitative 
point of view, it was important not to predetermine the issues patients would want to share, while 
at the same time creating a systematic framework for collecting details of patients’ experiences and 
health seeking behaviour in a form which, as far as we are aware, has not been used with this 
breadth before in Tanzania.  
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3. Findings 
3.1 The participants: socio-economic characteristics 
Most of the participants were undergoing cancer treatment when interviewed: 52 out of 62 (83%). 
The exceptions were in the regional hospitals, where half were on treatment when interviewed, and 
the survivors. 
Only adults were interviewed. The age range was wide, with the largest age group 45-54 (Figure 1). A 
majority (71%) were women.  
Figure 1 Ages of survey participants (years) 
 
 
Figure 2 Educational level of survey participants (percentage of all participants) 
 
A large majority of those interviewed had low educational levels (Figure 2). This was particularly true 
of those interviewed in public sector hospitals, mainly in Ocean Road. Of these, 90% (44 out of 49) 
had primary school education or below. Conversely, four of the seven patients interviewed at Aga 
Khan, and half of the survivors interviewed, had degree-level education.  
The majority of the study participants had been engaged in some form of economic activity before 
their illness (Table 2), the largest categories being farming, business and the professions. At the time 
of interview however, just over half stated that they were economically inactive (not working or 
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Table 2 Occupation of Respondents before Illness and when interviewed 
Occupation Before illness  When interviewed  
 Business (self-employed), casual worker 13 (21%) 8 (13%) 
Farmer (large or small scale, gardening) 27 (44%) 11 (18%) 
Employed professional e.g. teacher, 
doctor 
13 (21%) 10 (16%) 
Student 1 (2%) 1 (2%) 
Retired 2 (3%) 2 (3%) 
Not working 5 (8%) 30 (48%) 
Other unspecified 1 (2%)  
Total  62 62 
 
Declared household income levels at the time we met the participants varied widely, but 51% 
declared household income of under TZS 200,000 (less than USD 90) per month (Figure 3).  
Insurance coverage of some kind was held by 24% of participants, not including any in the lowest 
income band.  
Figure 3 Participants’ household income per month 
 
The study participants interviewed at the Ocean Road Cancer Institute (ORCI) and at the two 
regional public hospitals were predominantly from lower income households; a large majority were 
uninsured; and they were predominantly of lower educational background. The national cancer 
hospital thus genuinely appears to be serving, on this evidence, a wide socio-economic range of the 
population. Insurance cover of some kind was accessed during their pathways by 43% of the patients 
interviewed. However, while all but one Aga Khan patient and all but one of the survivors stated 
they held private, National Health Insurance Fund (NHIF), National Social Security Fund (NSSF)and/or 
employer insurance, only 31% of those interviewed in Ocean Road and the other public hospitals 
had accessed any insurance at all. Furthermore, these latter forms of insurance included a number 
of local schemes and forms of local fundraising, Community Health Insurance Fund (CHIF) and fee 
waivers, likely to provide much less financial support in total; only 6% of the public hospital 
interviewees had NHIF. No interviewee in the lowest household income bracket had any insurance 
access. The participants interviewed at Ocean Road, furthermore, gave home regions that were 
widely scattered geographically. Those interviewed at Kitete all gave Tabora as their home region, 
while at Tumbi, all but one participant was from Pwani region. All of the participants at Aga Khan 
gave their home region as Dar es Salaam, and most (83%) of the survivors interviewed did also. For 
the latter group, this reflects the method of recruitment.  
0 5 10 15 20 25
percent
no less than 400000 TSH per mont
between 300000 and 399999 TSH pe
between 200000 and 299999 TSH pe
between 100000 and 199999 TSH pe
between 50000 and 99999 TSH per
up to 49999 TSH per month
 
 
9 | P a g e  
 
3.2 Delays: extent and pattern 
As noted above, a high proportion of cancer patients in Tanzania have reached treatment only at a 
late stage in their illness, reducing the chances of effective treatment. The pathways narratives 
reported here provide substantial insight into the extent, nature and pattern of delays experienced 
by patients. The narratives begin from the first symptoms, and many patients experienced long 
delays between first noting the symptoms and receiving a cancer diagnosis.  
Not every pathway’s timeline can be measured accurately in terms of delays between stages, but 
most provide enough data for good estimates. Perhaps the most important measure for policy is the 
delay experienced between the first time a patient went to a formal health care institution with 
symptoms that turned out to indicate cancer, and reaching a diagnosis. The average delay before 
diagnosis for these patients was 2.13 years.  
The range however was very large as Figure 4 indicates. A quarter of these patients were facilitated 
to reach a cancer diagnosis within three months of first going with their symptoms to a health 
facility (not including a pharmacy or drug shop or alternative healer); 44% received a diagnosis 
within six months. Others had suffered longer or very long delays: 44% had waited over a year, and a 
quarter of respondents had waited two years or more.  
Figure 4 Years from first contact with formal health system to first cancer diagnosis 
 
Delays from diagnosis to treatment had been, fortunately, shorter (Figure 5).A quarter of the 
patients had started treatment within 2.4 weeks of diagnosis; 40% in under 6 weeks. However the 
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Figure 5 Number of weeks from first diagnosis to start of treatment 
 
The results of these delays, especially before diagnosis, are clear in terms of late stage presentation 
for treatment. Also clear is the potential well being benefits to patients of reducing those delays.  
We explore the pathways data here to disentangle sources of delay before diagnosis: the barriers 
and facilitators patients have faced in their search for a diagnosis.  
 3.3 How does starting point influence delay before diagnosis? 
Although some people waited too long before presenting their symptoms at a facility, most of the 
delay before diagnosis occurred after the patient had sought care in the formal health care system. 
Of 62 participants, just 20 narrated events addressing their symptoms (such as staying home, self-
medication from a pharmacy) before they first went to a health facility. The average delay before 
first going to a facility for that group alone was just under six months (median three months), with 
wide variation; the other 42 participants had gone straight to a facility.   
The pathways allow us to explore the extent to which the delay a patient experienced was 
influenced by their point of entry into the formal care system: the level of facility which they first 
visit. The results suggest some possible policy recommendations. 
Table 3 summarises, for all interviewees, the level at which they brought to the health system the 
symptoms later diagnosed as cancer, and the level at which they were diagnosed. Of the 49 patients 
interviewed at Ocean Road and the two at regional hospitals, most (69%) had started their 
engagement with the formal health system at a dispensary, health centre or district hospital 
(including the District Designated Hospitals (DDHs) with charitable status but within the public 
system). However 22% of those patients presented their symptoms directly to a zonal, regional 
referral or in one case national hospital. So as would be expected, patients on average needed to 
move “up” the hierarchy of the health system in order to find a diagnosis. However, some of those 
patients were diagnosed at district level. Most strikingly, as the patterns sketched in the figures 
below show, there was a huge amount of moving around, and “up and down” the system for many 
patients, as they tried to find out what was wrong with them. The length of time this search took 
was a key determinant of late or earlier presentation.  
Table 3 Level of entry into the formal health care system and level at which diagnosed 
Level of the health care system Level at entry (number of 
participants) 











5 10 20 40 60 80
Time from first diagnosis to starting treatment (weeks)
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Screening outreach  2 
Dispensary or health centre 17  
District hospital including DDH 18 4 
Other faith-based facility 2 4 
Private facility 11 13 
Regional referral hospital 8 8 
Zonal hospital 4 10 
National hospital 1 18 
Total 61 59 
Note: level of entry for one patient is unclear; level of diagnosis for three patients is unclear. 
Of the 13patients interviewed at Aga Khan or as one of the survivors’ group interviewees, 77% (10) 
had started at private facilities, and one at a regional hospital. Just two had started at dispensary 
level. Of these 13 patients, 8 (62%) had gone on to be diagnosed in the private sector, 3 at national 
hospitals, and one at a zonal hospital (for one, level of diagnosis is unclear).   
So how did these different starting points influence the time from first contact to diagnosis?  Table 4 
summarises the delays experienced before diagnosis, according to the starting point. Those who 
started in the private sector had experienced substantially shorter delays than the rest of the 
patients, and with relatively low variation. For the majority who started in the public sector, those 
who had gone directly to a zonal hospital had experienced the shortest average delays. Those who 
had started at district hospital level had waited on average about two years. The longest average 
delays were experienced by those who had started at a regional referral hospital or at a faith-based 
facility other than a DDH. (The very long delay when starting at a national hospital was the result of 
fear and refusal to take suggested tests.) 
Table 4 Time to diagnosis, by level of first contact with health system (years)  (all participants) 
Level of first contact N Mean time to 
diagnosis (years) 
Median time to 
diagnosis (years) 
SD 
Dispensary or health centre 15 3.14 1.08 6.95 
District hospital including DDH 18 2.02 0.65 3.30 
Other faith-based facility 2 6.66 6.66 8.98 
Private facility 11 0.69 0.37 0.91 
Regional referral hospital 7 2.35 2.09 1.84 
Zonal hospital 4 1.17 1.37 0.59 
National hospital 1 6.00 6.00  
Whole data set 58 2.26 0.92 4.30 
Note: Reliable data for the length of this delay are unavailable for4 patients, and for one of those, 
level of entry is unclear.  
The narratives of patients’ and survivors’ pathways to diagnosis allow us to explore the movement 
from facility to facility that patients experienced on the route from their starting point to a diagnosis. 
The median number of facilities visited up to diagnosis was 3, but many patients visited many more 
in their struggle to find out what they were suffering from (Figure 6). Just six people were diagnosed 
(sometimes after many visits) at the first facility they had approached.  
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Figure 6 Number of facilities visited from first visit to a facility to the facility where a cancer diagnosis was received. 
 
Figures 7-10 illustrate some aspects of these patterns. The figures show, to simplify a little, just the 
steps made between levels of the system, by the 57 patients for whom the data are clear enough to 
trace in this way. So they do not capture moves at the same level that are also counted in Figure 6. 
Many moves are “downwards” to a lower level as well as “upward” to regional, zonal or national 
level. These figures also do not capture of course the many times patients have returned to the 
same facility in search of answers. We are able to count some of those repeated visits by totalling 
the number of “events” into which our participants divided their experience: this is quite a good 
indicator of total visits. The median number of events between first contact and diagnosis was 5, 
average 6, but 25% of the respondents recounted between 7 and 27 events from start to diagnosis.  
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Figure 7 Movements between levels of the health system from first contact to diagnosis: those starting at dispensary 
level 
 
Of 14 patients who had presented their symptoms first at a dispensary or health centre and for 
whom we can identify the level of diagnosis, Figure 7 shows what happened next. Purple lines are a 
direct move from the start to the level where diagnosed; red lines are two moves across levels to 
diagnosis. Blue lines are single moves between levels by patients making three moves or more. Thus, 
four patients went from a dispensary directly to the level where diagnosed: one at district level (all 
district hospitals include DDHs), the others at a private, a faith-based and a zonal hospital 
respectively. Eight other patients went first from dispensary level to a district hospital (one army 
hospital is included here), from which three moved directly on to the level at which diagnosed (two 
in a zonal hospital, one in a faith-based facility). The remaining 50% of patients who started at a 
dispensary moved around much more, up and down the system (the blue arrows, one per move), 
experiencing three or more moves between levels and sectors of the system before diagnosis. The 
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Figure 8 Movements between levels of the health system from first contact to diagnosis: those starting at district 
hospital/ DDH level 
 
The experiences of 18 patients who went directly with their symptoms to a district hospital suggest 
some reasons why the pattern of moving “up” the system in search of a diagnosis may cause delays. 
Of these, two were diagnosed with cancer at the district facility they first approached, and two more 
went directly to the national level where they were diagnosed. However, for the others, the most 
common route was to go “up” to a regional hospital (Figure 8), but none were diagnosed at that 
stage. All had to move on to another level at least once in order to reach the level where they were 
diagnosed (Figure 8). Four others went to zonal or faith-based hospitals, and were also not 
diagnosed there. Some people went “down” to a dispensary or district hospital and then “back up” 
to a level where diagnosed.  This “churning” is a clear source of delay, and was associated in many 
cases with severe pain and worsening symptoms. Figures 7 and 8 show that many patients had to 
reach national level before a diagnosis was obtained, rather than being diagnosed lower down and 
then being referred for treatment. 
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Figure 9 Movements between levels of the health system from first contact to diagnosis: those starting at regional, zonal 
or national level 
 
So did it speed up access to diagnosis if a patient went directly to a higher level hospital, regional, 
zonal or national, when first symptomatic?  Table 4 suggests this is the case for the zonal but not the 
regional hospitals. Figure 9 backs up this perception.  Of the 12 patients who started at this level, 
two were directly diagnosed at the zonal hospital they first approached; three moved in one step to 
another regional or zonal, or a private hospital where they were diagnosed.  But others moved up 
and down the system a striking amount: this is an unfavourable level of churning given these 
patients’ relatively high-level start. The surprise lies in the expectation that these higher level 












16 | P a g e  
 
Figure 10 Movements between levels of the health system from first contact to diagnosis: those starting at faith-based 
or private facilities 
 
Finally, Figure 10 shows the more direct trajectories experienced by patients who started in the 
private sector including independent faith-based facilities. As Table 4 showed, those starting in the 
private sector had the shortest average pathways. Of those who started at a private facility, two 
were directly diagnosed there, and eight made one or two more steps. Only one had a complex 
pathway in terms of movement between levels, and this person began at a private laboratory 
outside Dar es Salaam. One person starting at a faith-based facility went on to a regional hospital, 
but was not diagnosed until they joined a screening exercise.  
Several patterns emerge from these mapping exercises.  
First, rather few participants, 6 out of 58 for whom data are complete, were diagnosed at their point 
of entry: two at a district hospital, 2 at a zonal hospital, 2 at a private hospital, sometimes after 
multiple visits to that facility. Everyone else had to move around, including between levels of the 
system, to find a diagnosis. So speed of that movement was one determinant of extent of delay. It 
follows that reducing the widespread experience of apparent misdiagnosis or mistaken reassurance 
at the point of entry, thus increasing the chances of diagnosis at point of entry, would help to 
“down-stage” cancer diagnoses and treatment.  
Second, particular dispensaries and district hospitals have done well in several these narratives.  Two 
of the direct diagnoses were at district level, and two other patients starting at district level moved 
directly to national level for diagnosis (Figure 8 purple arrows). Of those starting at dispensary level, 
four moved just one level to be diagnosed (Figure 7 purple arrows). This suggests there is some good 
practice in the lower levels of the health system, at picking up dangerous symptoms and indeed at 
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diagnosis, and that this practice could be built on to speed up pathways to diagnosis and treatment. 
(We discuss the evidence on formal referral further below.) 
Third, the performance of regional hospitals appears to be both important to speeding up diagnosis, 
and also, in these narratives, appears particularly problematic. A high proportion of these 
participants had pathways that included consultations at regional hospitals, as part of “churning” 
between regional and faith-based or private facilities. Nearly half of those who started at district 
level moved from there to regional level (Figure 8) but none were diagnosed at that stage, all moving 
on to other levels before diagnosis. No patients were diagnosed at point of entry at a regional 
hospital. Only 8 people in total were (eventually) diagnosed at regional level (Table 3); while those 
starting at regional level suffered longer delays on average than those starting at district level (Table 
4). This strongly suggests that sharply improving diagnostic capacity at regional hospitals would help 
to reduce average delays across the system.   
Fourth, two patients in this data set were finally diagnosed through one-off screening events 
(Figures 8 and 10) both having previously presented their symptoms at a regional and a district 
hospital respectively. This does suggest the potential benefits from integrating screening into 
primary care.   
In contrast, those participants starting in the private sector had suffered substantially less 
“churning”, with those not diagnosed in the private sector moving more directly to the national level 
(Figure 10). Two out of 13 were diagnosed at point of entry into the system; four more moved one 
level to find a diagnosis and five others just two steps (Figure 10 purple and red arrows). The shorter 
delays involved (Table 4) do suggest the scale of benefits available from reducing “churning” for all 
patients. Furthermore, the narratives from the whole data set pick up the importance of private 
facilities also in diagnosis: a number of the movements to the private sector, for example in Figure 9, 
were for diagnostic testing in private facilities and laboratories. In all 12/58 diagnoses were in the 
private sector (Table 3).  
Finally, the qualitative information in the narratives identifies another major cause of delays: long 
waits for tests and for results from tests. There are many cases where patients have waited months 
for results; had to repeat tests; and have as a result spent large sums out of pocket. It is clear there 
are major limitations on the ability to take and process biopsies.  Here are just a few examples: note 
that in most cases the text is researchers’ summaries of responses; where direct speech is quoted as 
recorded by the interviewer, this is in quote marks.  
In Muhimbili, a patient was admitted for a series of tests including CT scan, X-ray, ultra-
sound. The wait for the biopsy results was two months.  
A patient was referred from a regional to a private hospital to have a biopsy taken. It seems 
the result was never available. Three months later the regional hospital took a repeat biopsy 
themselves and sent it to Muhimbili. Two months later the patient received the results at 
Muhimbili. 
Cost also delayed biopsies:  
At a zonal hospital, a patient with a breast lump was given an ultra sound and X-ray, and 
“they wanted to take sample from my breast, but I didn’t have extra money”, resulting in 
another five months’ delay. The total OOP cost of the repeated tests including the later 
biopsy was TZS 190,000.  
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3.4 The scarcity of formal referrals: “patient management” of the search for a 
diagnosis 
To what extent are the moves patients make between facilities, both at a particular level and 
between levels, the result of formal referrals? The question is relevant because most moves before 
diagnosis appear to have been the patients’ own decision. We identified all the movements between 
facilities when respondents said that they were referred, or that they had a referral letter. On this 
measure only 15% of the total movements between facilities depicted in Figure 6 (an average of 3.5 
moves between facilities), and partially mapped in Figures 7-10, were associated with a formal 
referral. All the others were the patients’ own decisions, made often with family or friends’ advice, 
or sometimes following a suggestion from one facility staff member that they should go to another 
facility. 
To look at this another way, nearly half (30out of 62 respondents, 48%) had never been formally 
referred at any point between initial contact with the health system and arrival at a diagnosis, 
despite all the “churning”. Of the others, 6(10%) had been diagnosed at point of entry (hence, 
referral for diagnosis was not required). The other42% had received at least one formal referral (in 7 
cases, two) for one (or two) of their many moves on their way to a diagnosis. Everyone had moved 
more often than they had been referred, except for the six diagnosed at entry.  
This finding underlies the narrative evidence in these data that, before a cancer diagnosis, when 
time is key to survival, patients suffered frequently very severe symptoms while waiting for a 
diagnosis. Their many moves from facility to facility were made, according to their own descriptions, 
dependent on their own and others’ assessment of accessibility, affordability and likelihood of 
gaining help. All patients given a referral at some point had also thus spent time moving between 
facilities without professional guidance. In effect, the health system’s “pathways” to diagnosis are 
being shaped overwhelmingly by the patients’ own care-seeking behaviour. The result is the erratic 
and complex movement patterns shown on Figures7-10, and a great deal of confusion and suffering. 
These patterns generated lengthy delays (an average of 2.13 years) and the very severe symptoms 
recorded in these narratives before many patients reached a diagnosis.  
The pattern of referrals experienced did vary somewhat, but not greatly, by level of entry. Of those 
who started at district hospitals, 67% were either directly diagnosed at that level or had a formal 
referral at some point in their pathways to diagnosis.  For those who started at zonal level that figure 
was 50%. For those who started at a private facility, and for all other patients together, that figure 
was 45%.   
Furthermore, referrals when they were offered had not always accepted, often for cost reasons: 
patients were sometimes unable to afford tests. Referral patterns where they happened were 
complex. There was considerable churning, not only movement up the levels to the national 
hospitals, but also “sideways” and “down”. Two people were referred from public to private facilities 
for tests, both from regional referral hospitals. In one case, a dispensary aimed to send a patient 
directly to the national level, but this referral was refused (reason unstated) and the patient took 
themselves instead to a regional hospital. Another patient refused a regional to national referral 
because they “were advised” that it would be too expensive. A referral from dispensary to a faith-
based hospital was also refused for lack of funds. 
3.5 Cost as a barrier to reaching a diagnosis 
As the refusals of referrals illustrated, out-of-pocket costs are a known barrier to accessing care. 
Only patients who have succeeded in remaining in the system could be interviewed, so we have no 
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accounts of experience of those who have had to drop out of a search for diagnosis because of 
inability to pay. The figures in this subsection are the payments made by patients who reached a 
diagnosis and are still in the system. Patients also commented on the problems of raising funds, and 
we quote those experiences below. 
While cancer treatment in the public sector should be free of charge (Miranda, 2016), the 
consultations and tests are not, before being diagnosed with cancer. These costs can be high. 
People’s memories of payments at each stage of their pathways were often quite sharp. In the 
findings that follow, the data are of course for the payments that people recalled. The out-of-pocket 
(OOP) payments summarised in Tables 5 and 6 are likely to be underestimates therefore, but they 
still give an indication of the burden of OOP payments on cancer patients before diagnosis.  
In Tables 5 and 6, the average payments reported are payments by people who could remember the 
payments for two thirds of the events recorded. This is most of the respondents: 55 out of 62. We 
report the data in this way to reduce the extent of underestimation.  
These patients had spent on average a recordedTZS411,831 out of pocket (OOP) on consultations, 
tests and treatments including surgical investigations before and up to arriving at a diagnosis. The 
range of payments was very wide, with 26% having made no out-of-pocket payments, and a top 
payment of TZS4 million. These levels of payments form a particular barrier for those from low 
income households.   
Table 5 shows average payments out-of-pocket for care (not including transport) by declared 
household income band before diagnosis. Averages are distinguished between patients who 
recorded access to some type of insurance, and those with none.  
Table 5 Mean out-of-pocket spending from first contact with the health system to diagnosis, by income band and 
insurance status (TZS) 
Income bands Mean OOP spending by income band Number of 
respondents 
  Not insured  Insured   All patients  
Up to 49,999 TZS/month 618,167  618,167 3 
50,000 to 99999 TZS/month 445,600 98,333 350,892 11 
100,000 to 199,999 TZS/month 213,667 570,700 302,925 8 
200,000 to 299,999 TZS/month 773,333 14,666 394,000 6 
300000 to 399999 TZS/month 308,000 34,000 183,455 11 
400000 TZS/month and above 1,310,250 444,546 633,188 16 
All participants  537,010 272,517 411,831 55 
 
Table 5 strongly suggests that costs before diagnosis have been a major burden, especially for those 
in the lowest household income category, none of whom had access to any insurance.   As Table 5 
shows, insurance seems to have offered some protection against out of pocket spending before 
diagnosis, but this is limited before diagnosis and treatment, and in one household income band, 
those with insurance had paid more on average.  
Table 6 explores this burden further. The “household burden” is calculated by dividing out-of-pocket 
spending up to diagnosis by annual declared household income. Again these data include only those 
who could recall payments (including zero payments) during two thirds of their events.  
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The average burden is 22% of household annual income, but the variation is huge. In particular, the 
burden on the two lowest income categories really stands out: patients from the lowest household 
income category had spent on average more than the annual household income; the next lowest, 
48% (Table 6 column 4). Above that income level, the average burden falls below 20%. Having some 
access to insurance appears to have offered some protection, particularly at higher income bands 
(Table 6 columns 2 and 3), but not in all lower bands.  
Table 6 Household burden of OOP payments from first contact with the health system to diagnosis, not including 
transport (multiple of annual household income) 
Income bands Mean burden by income band N % with 
insurance 
  Not insured  Insured   All patients   
Up to 49,999 TZS/month 1.17  1.17 2* 0 
50,000 to 99999 TZS/month 0.60 0.16 0.48 11 25 
100,000 to 199,999 TZS/month 0.12 0.42 0.20 8 20 
200,000 to 299,999 TZS/month 0.32 0.01 0.16 6 44 
300000 to 399999 TZS/month 0.08 0.01 0.05 11 45 
400000 TZS/month and above 0.14 0.08 0.09 16 73 
All participants  0.34 0.09 0.22 54 41 
* One very low income household declared zero current income so the burden cannot be calculated.  
As Table 6 shows, 41% of interviewees declared some access to insurance. However, the types of 
insurance varied greatly. Just seven people stated that they held private commercial insurance (AAR, 
Jubilee, Strategis). All but one were in the highest income band, one in the band below. A number of 
people used several forms of insurance: thus twelve people held NHIF, two NSSF, two had some 
insurance from an employer: 13 people in all since some people had more than one, and one also 
held private insurance. Of those holding NHIF or NSSF or employer insurance, 70% were in the top 
two income bands. Seven people used some form of local insurance or facility financial support, 
again sometimes more than one: CHF (just one person), local schemes (unspecified), Standing Voice 
(a charity for those with albinism) and exemptions for age or pregnancy or poverty. Those using local 
schemes and charitable funds were all in the three lower income categories. Thus insurance access, 
as expected differs sharply by income.   
Of those holding private commercial insurance, all had started at a private facility; conversely only 
one person starting at a private facility did not have either private insurance or NHIF. Of those 
holding NHIF/NSSF/employer insurance, 30% started at a private facility; the rest in the public sector 
and almost all at a dispensary or district hospital. Those using some form of local insurance or 
exemption had all started in the public sector and mainly at lower levels. The implication is that 
insurance and delay are associated, as we would expect (Table 7).  Those with private insurance, 
with the option they mainly take up of starting at private facilities, have sharply lower delays before 
diagnosis. The delay advantage given by NHIF, NSSF or employer insurance is much less. 
Table 7 delay between first contact with the formal health system and diagnosis, by type of insurance held (years) 
Type of insurance Mean delay Median delay N 
Private insurance 0.54 0.04 7* 
NHIF, NSSF, employer insurance 1.17 0.50 12 
CHF, local religious and charitable funding 0.99 1.16 5 
No insurance 3.01 1.08 34 
Note: one person with “unspecified” insurance omitted. 
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* Includes one person also holding NHIF.  
Insurance however rarely helps with transport costs. As is well known, transport costs and 
geographical access often constitute major barriers to care. Payments for transport were high 
relative to income, and insurance was not generally available.  Furthermore, travel to regional or 
zonal or national hospitals could involve transport costs for others accompanying, and food and 
lodging. Sometimes, the ability to take up a referral for a diagnosis – or go to a recommended 
hospital in search of a diagnosis - could depend on whether a family had relatives or friends in a 
town or city who could house them while undergoing tests.  
These patients had spent an average of TZS 48,425 on transport and travel costs before and up to 
diagnosis (Table 8). For the lower income patients, travel posed a severe and sometimes prohibitive 
barrier. 
Table 8 Transport costs from first symptoms to diagnosis, by household income bands 




Up to 49,999 TZS/month 93,963 4 
50,000 to 99999 TZS/month 45,283 12 
100,000 to 199,999 TZS/month 23,900 10 
200,000 to 299,999 TZS/month 112,655 9 
300000 to 399999 TZS/month 21,690 11 
400000 TZS/month and above 36,972 16 
All participants  48,425 62 
 
3.6 Costs, referrals and the move to treatment 
Cancer treatment is formally free in Tanzania in the public sector for those without insurance, 
though not all of the patients interviewed had been aware of that before arrival at Ocean Road. 
However, after diagnosis, patients interviewed had still faced many costs, including tests and 
treatment costs, as well as continuing transport cost challenges.  
The analysis that follows breaks down the non-transport OOP costs into two categories: those 
incurred between diagnosis and starting treatment, and treatment costs. Not all of our interviewees 
were undergoing treatment. Some were awaiting treatment, and some, in the survivors’ group, had 
finished treatment and were returning for check-ups. Table 9 shows the OOP payments made by 
interviewees between diagnosis and beginning of treatment.  
Table 9 Total OOP payments from diagnosis to start of treatment, not including transport (TZS) 
Income bands Mean OOP spending by income band N 
  Not insured  Insured   All patients  
Up to 49,999 TZS/month 63,500  63,500 4 
50,000 to 99999 TZS/month 527,775 145,000 423,381 11 
100,000 to 199,999 TZS/month 223,750 140,785 207,157 10 
200,000 to 299,999 TZS/month 45,400 0 25,222 9 
300000 to 399999 TZS/month 57,833 42,500 47,000 11 
400000 TZS/month and above 2,762,500 7,272,727 5,690,625 16 
All participants  518,829 3,120,637 1,619,291 61 
Note: one respondent omitted for whom over half the payments could not be recalled. 
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The variability of these payments is very high. But what stands out is a continuing burden. While 
cancer treatment is free at treatment point, a cancer diagnosis triggers, on average, burdensome 
continuing costs. Not all patients however suffered these costs. Half (31) of these patients had made 
no OOP (non-transport) payments between diagnosis and starting treatment, and of those, 65% (20) 
were insured. Of the others (30) who had incurred these costs, 80% were not insured. Furthermore, 
80% of the top income bracket made no OOP payments at this stage. It seems therefore that after 
diagnosis, insurance became more protective, in the sense of increasing the likelihood of paying 
nothing. However, those who paid out of pocket in some cases paid a great deal, especially if going 
abroad. (We return to travel abroad below.) 
The following are some examples of these continuing costs within Tanzania: 
A patient diagnosed with cervical cancer at a regional hospital was referred to Ocean Road; 
from there, was referred for surgery at Muhimbili National Hospital at a cost of TZS 790,000, 
paid by the family. 
A patient diagnosed with cancer at Muhimbili National Hospital was referred to Ocean Road 
where the family paid TZS 150,000 for a biopsy and X-ray; after that chemotherapy 
treatment was provided free of charge. 
A patient admitted at Ocean Road (free of charge) was asked to go to a private hospital for a 
CT scan; the TZS 250,000 cost was paid by the family. 
Surgery, tests and blood transfusions seem to have been items that quite commonly incurred 
charges after diagnosis and before first treatment. 
Transport costs can also be a barrier at this stage, especially where treatment requires a move to 
Dar es Salaam. The average transport costs are lower than before diagnosis (Table 10), reflecting 
fewer moves. But costs could still be prohibitive, especially when people needed to find 
accommodation in Dar es Salaam where they had no relatives (Box 1). Of those who incurred 
transport costs over TZS 50,000 at this stage, over half (7 out of 13) were in the two lowest income 
bands.  
Table 10 Transport costs from diagnosis to starting treatment, by household income bands (TZS) 
Income bands Mean travel spending 
by income band (TZS) 
Number of 
respondents 
Up to 49,999 TZS/month 57,250 4 
50,000 to 99999 TZS/month 46,120 12 
100,000 to 199,999 TZS/month 35,625 10 
200,000 to 299,999 TZS/month 25,950 9 
300000 to 399999 TZS/month 33,827 11 
400000 TZS/month and above 11,214 16 
All participants  28,993 62 
 
Box 1:“I was living at the bus stand” 
This patient with skin cancer was diagnosed at a district hospital, where a lump was 
removed without solving the problem. Offered a referral to Ocean Road for radiotherapy, 
the patient initially refused, citing the need to raise funds. The patient first tried a local 
healer, who seems to have charged TZS 1,500,000 (about USD 750). Four months later the 
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patient accepted the referral and travelled to Dar es Salaam, where the diagnostic tests 
were repeated and the patient had surgery at Muhimbili (costing TZS 180,000 plus transport 
cost TZS 39,100, about USD 110 in all). However, the patient had no money for 
accommodation nor relatives in Dar es Salaam, so: “during all this process and waiting time, I 
was living at the bus stand”, while suffering severe pain and waiting to undergo surgery. 
There was then a two month wait to see a doctor and then to start chemotherapy at Ocean 
Road followed by radiotherapy: however at that point, free treatment started, so the patient 
was then incurring only transport costs during treatment (totalling around USD 100 to date).  
 
People moved less between facilities between diagnosis and treatment than when they were 
searching for a diagnosis, and were much more likely to have been referred at that point than before 
diagnosis. The median number of moves between facilities from diagnosis to treatment was just 1 
(average 1.6), and 14 people did not move: they were treated where they were diagnosed. Of the 
rest, who made at least one move, two thirds had received at least one referral. All those who 
moved several times had at least one and often several referrals.  It therefore seems that the 
referral process works more effectively after diagnosis than before, which is likely to be a factor in 
reducing delays.   
Many of the moves between facilities after diagnosis, furthermore, were purposive in the sense that 
they were the result of referrals or proposed moves for tests or treatments not available elsewhere. 
There was some repetition of tests at this stage, and while repetition may be necessary to identify 
the most desirable treatment, it would be relevant to see whether such repetition could be 
minimised.  
3.7 Costs of treatment and travel abroad 
As noted above, not all our interviewees were undergoing treatment at the time when interviewed. 
Of 62 respondents, 11 had either completed treatment or had not yet started. Of the 51 
respondents on treatment, 32 had paid nothing out of pocket for treatment to date. Of those paying 
nothing out of pocket, half had no insurance, suggesting the free treatment policy is fully protective 
of some patients.  Of those paying something (included in Table 11), two thirds had no insurance. 
Conversely, of those with private insurance, only 1 out of 4 had paid OOP during treatment; of those 
with NHIF/NSSF or employer insurance, 8 out of 11 had paid nothing. This suggests that both the 
free treatment policy, and insurance are protective, but not completely.  
Table 11 shows the OOP payments made by the date of interview by those on treatment. These 
sums are large in relation to household incomes. In addition, average travel costs within Tanzania for 
those on treatment, after the start of treatment, were over TZS 89,000, with very wide variation.   
Table 11 OOP payments by those undergoing treatment whose OOP payments>0 (not including transport where 
treatment is in Tanzania) (TZS) 
Income bands Mean OOP spending by 
income band (TZS) 
No of respondents paying OOP 
costs while treated 
Up to 49,999 TZS/month 90,000 2 
50,000 to 99999 TZS/month 1,317, 133 3 
100,000 to 199,999 TZS/month 1,361,333 3 
200,000 to 299,999 TZS/month 741,750 4 
300000 to 399999 TZS/month 93,500 2 
400000 TZS/month and above 7,109,480 5 
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All participants  2,469,305 19 
 
One option open only to those with very good insurance cover or high incomes – the two are likely 
to be closely correlated – is to move abroad for treatment, or indeed for diagnosis. Among our 
interviewees are 6 cancer sufferers who have been to India and to South Africa for treatment. Two 
travelled to India for a PET scan; in each case the treatment cost was paid by private insurance. One 
patient paid around TZS 2 million out of pocket for treatment in South Africa and diagnosis in India, 
but also had Indian treatment paid by NHIF, NSSF and an employer. The other three paid large sums 
out of pocket: the average OOP payment for those three was over TZS 160 million, in addition to 
substantial coverage of overseas costs by NHIF and private insurance. These overseas OOP totals 
include travel costs.  Of the 19 respondents included in Table 11, the OOP payments for four include 
these overseas costs, paid by patients from households in one of the two upper household income 
bands. 
3.8 Alternative treatments: reasons, costs and delays 
When people were asked about complementary and alternative treatments, two major categories of 
response stood out: those who found strength in prayer and faith healing, and those who consulted 
alternative healers. Out of 62 respondents, 34 (55%) had recourse to options other than biomedical 
health care. In the answers on why people used alternatives, several themes stand out.  
The first is prayer and healing.  Hope and belief led people to include prayer and religious healing in 
their search for a cure: 11people said they had taken this route, noting the support it offered. For 
example: 
“I’m a born-again Christian, so I believe in prayers.” 
 
“Treatment goes in hand with prayers.” 
 
She visited church hoping that God will do miracles because of the problem she was facing. 
 
“We are connected through faith, so by praying I felt healed.” 
 
Sometimes, prayer was associated with financial support from a mosque or church community.  
 
The second route was to consult alternative forms of treatment. Some people who did so followed 
advice, or had seen beneficial effects for others. Some felt strongly pressured to take this route. 
Some feared that cancer was induced by witchcraft, and sought help to reverse that. Others simply 
felt that in the face of cancer, and in severe pain, people should try everything. Here are some 
examples of these responses:  
 
“Someone advised me to visit a traditional healer, I visited him twice.” 
 
“I was compelled by my mother, yet they didn't work out.” 
 
He thought maybe the sickness was related to witchcraft thus why he went for alternative 
treatment. 
 
“When you are sick, all you wish for is recovery, so you could try anything.” 
 
“So much pain, hoping for some pain relief.” 
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“I saw my neighbours and friends healing so I wanted to try my chances of healing.” 
 
These sentiments of course overlap, and in the absence of clear clinical pathways to diagnosis and 
treatment, this combination of care-seeking with belief and fear is a potent mix. It led many to plead 
for more information to be available as well as more access to conventional care. One person 
regretted their alternative care-seeking behaviour:  
“I thought it could help me, but to be honest it delayed the process hence the problem grew 
up.” 
Visits to traditional healers can be expensive, as Box 1 suggests. Several interviews seem to imply 
that it may be easier to raise money locally for traditional treatment than, for example, for transport 
to Dar es Salaam after a referral. The average OOP payment to alternative healers by the 15 people 
who provided these costs was a startling TZS 484,467. The payments varied from TZS 5000 at the 
lower end to TZS 6 million at the top; the median payment was TZS 30,000.  
Those who gave reasons for avoiding traditional healing made it clear that these decisions are a 
matter of belief in a time of acute uncertainty. Some said that their religious beliefs required them 
to avoid traditional healers: for example: “my faith doesn't allow *this+”. Some simply did not believe 
in the power of traditional healing, or were afraid: for example: 
“I don't believe in traditional treatment, I am educated.” 
“Traditional herbs don't heal cancer.” 
“I am afraid of traditional healers.” 
Some responded by expressing a firm belief in medical/ hospital treatment, for example:  
“I believe that the only safe place for treatment is in hospital.” 
“I believed and I still believe that I will be healed in hospital.” 
“Because I believe cancer can be treated and cured.” 
The underlying theme here is the need for belief in the absence of much information.  Unsurprisingly 
therefore, when participants were asked for further comments, some emphasised education and 
information.  
3.9 Patients’ perspectives on their experience: acceptability, failures and additional 
commentary 
When asked about sources of support, most people (79%) said family; 19% said friends; while 9 
(15%) said neither of those two groups. In all 14 (23%) cited community, local, group and voluntary 
support. The latter percentage is not large, focusing attention on a lack of wider social support, 
associated with the stigma some have experienced. Furthermore, overwhelmingly (94%), people said 
their ability to work have been affected by their illness.  
When asked about the acceptability of different aspects of treatment, there were rather few 
responses; two people said they had refused radiotherapy as unacceptable, and one had refused a 
mastectomy on the same grounds.  
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Finally, respondents were asked: “Is there anything else you would like to tell us?” Strikingly, almost 
all had more to say, despite the stress of these interviews, and many made several different points. 
These detailed responses have been analysed for themes, and several key themes stand out. 
First, as noted above, several people identified the need for much more education and information.  
Some comments linked lack of information and stigmatising of cancer patients: 
“Cancer education is needed in the society. I wish I knew that it was cancer right from the 
start, [then] I wouldn't suffer that much. The education should be extended from primary 
school to universities. Another thing is that there is stigmatization of cancer patients, as 
people think that once you get it, you must die. Had there been no such feelings, patients 
would be free to share [experience?] and get advice.” 
“More outreach programmes should be conducted. Some people think cancer is a 
communicable disease, so we need to make people aware of the disease and what the 
possible causes are.” 
Some linked the need for a public health education strategy for cancer to the acknowledged need 
for screening:  
“People in the village should be given education concerning the cancer also they should be 
examined for cancer because many people there don’t know about cancer.” 
“Women should go for screening more often, early detection of cancer greatly increases the 
chances for successful treatment.” 
And another noted that there was a need to combat disinformation:  
“Cancer awareness should be publicized, in order [for] people to get rid of talking 
nonsense.” 
There were also comments on the need for specific information: 
“I was wondering if there is any food that I can eat which can help with this disease.” 
A second theme in these comments was the interlinked problems of costs of travel and treatment 
and associated impoverishment, and some considered remedies. Some cited examples of 
impoverishment:  
Cancer disease has made her poorer economically because she sold some of her farmland in 
the rural area. 
“I normally suffer a lot because I don’t have capital to continue with my business.” 
Even with free treatment at Ocean Road, other costs can be prohibitive or reduce the effectiveness 
of treatment:  
“I don’t have any relative here, the medicines are very strong, I need to eat fruits and good 
food. Therefore I need money.” 
There was strong support for the principle of free treatment. Those with insurance recognised they 
were “lucky”. Some respondents noted the limits of current policy on free care, and its effects:  
“I wish to go for check-up again but I cannot afford it.” 
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Transport costs were identified as a major barrier, and one person linked this to the fear of having to 
pay that kept some from accepting referral:  
“From the time I got results to date, more than six months I haven't reported to Ocean Road 
hospital, because I do not have money. I can't afford even a bus fare to go to this referral. In 
addition to that people say that it is so expensive to deal with cancer so I decided not to go.” 
Financial support was recommended, and it was noted this would help with continuing economic 
activity by patients:  
Grant/loans to patients to be able to stay as an active contributor in the society. 
The most common single theme in the responses was however the need to bring cancer treatment 
closer to home, to reduce costs, to help to increase speed of response, and to increase accessibility. 
Comments included services and also medicines and equipment:, for example:  
“Government should try to extend cancer services to other regions or zones to reduce cost 
of transport and availability of chemotherapy and radiation.  I understand that many 
patients are in the regions, they fail to come to Dar es Salaam.” 
Cancer services should be available also to the District and Regional hospitals. 
Cancer drugs should be available at Regional hospital pharmacies to reduce transport costs 
of patients going to receive it at Ocean Road Cancer Institute 
“Those machines used for treatment should be available at rural areas hospitals so as to 
reduce the population of people from rural areas who come here for treatment.” 
One patient noted that there is some cancer treatment available in the regions, but it can be costly: 
“The government should consider providing a free cancer care at KCMC hospital in Moshi 
like here at Ocean Road Hospital because the costs are so high there.” 
In addition to geographical distances, patients noted there were other sources of delays in the 
system which made patients’ condition worse. These included slow receipt of test results: 
“The tests results should at least come out in a short duration. Like my biopsy back home 
took 2 months.” 
Equipment and supplies problems and queues were also mentioned: waits for equipment availability 
and long queues: 
“The queue is big here at Ocean Road Cancer Institute for treatments like chemotherapy.” 
“For example in MNH [Muhimbili National Hospital] we were using one bed for 3 people 
during chemotherapy sessions so at times you can’t even sleep.” 
And finally, in these comments there was deep appreciation for Ocean Road hospital’s efforts, 
alongside the desire to spread this care across the country. 
She thanks Ocean Road hospital for the good care and adding radiation machine. 
Also commended the good services provided by Muhimbili National Hospital and Ocean 
Road Cancer Institute. 
And there was even laughter at this mix of stress and care: 
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(Laughter) “what I can say, I am thankful for services provided at Ocean Road Cancer 
Institute and other hospitals  should imitate Ocean Road Cancer Institute on how to care for 
cancer patients.” 
4. Conclusions and recommendations 
This paper’s key findings identify some reasons why many cancer patients start treatment at a late 
stage of the disease. Factors identified as barriers within the long pathways to diagnosis measured 
here included missed opportunities to pick up symptoms early, and many resultant moves between 
facilities as patients sought information and care. Most of this “churning” was not formal referrals: 
referrals became more common after diagnosis. Other factors included the burden of out of pocket 
costs of care and transport, and the fears and frustrations that led to recourse to alternative 
treatment and self-medication. The paper documents a higher cost burden for those in the lower 
income bracket without insurance coverage. Once a patient was diagnosed the treatment became 
free for many, but patients bore some costs to access to medication and tests, especially when 
facilities lacked essential prescribed items.  
The Government should build the capacity of regional hospitals to be able to make and confirm 
diagnosis of cancer. Enhancement of efficiency and adequacy of service delivery at the lower tier 
facilities is necessary to reduce the burden on the patient’s journey. Cancer care also requires an 
efficient fast-tracking referral process for those diagnosed or suspected of having cancer. Some 
lower tier facilities should also be enabled with human resource and equipment to facilitate early 
and timely diagnosis as well as treatment.  There is a need to assess how innovation in diagnosing 
and cancer treatment can lower costs of treatment and care, enabling timely referral and to reduce 
the overall costs of treatment and overhead expenses. Furthermore, the government should 
consider a grant or financial support for the low-income patients of cancer to facilitate their reaching 
to the hospitals and access appropriate treatment timely. Additionally, the foundations or 
associations for cancer survivors could also undertake fundraising activities with the private sector, 
and work with hospitals to support patients who cannot afford to reach the referral hospitals for 
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